Estrella Immunopharma, Inc. (ESLA)
NASDAQ: ESLA · Real-Time Price · USD
0.6915
-0.0335 (-4.62%)
Sep 1, 2026, 4:00 PM EDT - Market closed

Estrella Immunopharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Jun '24 Jun '23 Jun '22
Operating Income
-9.68-13.06-8.85-7.31-11.11-1.69
Net Income
-10.01-13.06-8.85-7.31-11.11-1.07
Earnings Per Share
-0.25-0.35-0.24-0.27-36.35-
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Jun '24 Jun '23 Jun '22
Cash & Investments
0.151.380.924.172.484.09
Total Debt
-0.01000.02-
Net Cash (Debt)
0.151.380.914.162.464.09
Net Cash Growth
-88.83%50.98%-78.06%69.36%-39.90%-
Net Cash Per Share
0.000.040.030.158.04-

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Jun '24 Jun '23 Jun '22
Operating Cash Flow
-9.38-1.79-7.64-16.07-1.34-1.44
Free Cash Flow
-9.38-1.79-7.64-16.07-1.34-1.44
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.